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Introduction: Treatment-resistant depression (TRD) is a debilitating condition affecting
20–30% of patients with major depressive disorders (MDD). Currently, there is no
established standard of care for TRD, and wide variation in the clinical approach for
disease management has been documented. Real-world data could help describe TRD
clinical features, disease burden, and treatment outcome and identify a potential unmet
medical need.
Methods: We analyzed the Italian data from a European, prospective, multicentric,
observational cohort study of patients fulfilling TRD criteria by the European Medicine
Agency, with moderate to severe major depressive episode, and starting a new
antidepressant treatment according to routinary clinical practice. They were followed
up for minimum 6 months. Treatments received throughout the study period, disease
severity, health-related quality of life and functioning were prospectively recorded
and analyzed.
Results: The Italian subcohort included 124 TRD patients (30.2% of patients of the
European cohort; mean age 53.2 [sd = 9.8], women: 82, 66.1%). At enrollement, the
mean (SD) duration of MDD was 16 years (sd = 11.1) and the mean duration of the
ongoing major depressive episode (MDE) was 97.5 weeks (sd = 143.5); low scores
of quality of life and functioning were reported. The most frequently antidepressant
classes started at baseline (data available for 98 subjects) were selective serotonin
reuptake inhibitors (SSRI, 42 patients [42.9%]) and serotonin-norepinephrine reuptake
inhibitors (SNRI, 32 patients [32.7%]). In terms of treatment strategies, 50 patients
(51%) started augmentation therapies, 18 (18.4%) combination therapies and 24 (24.5%)
monoterapies (6 patients [6%] started a non-antidepressant drug only). Fourteen patients
(11.3%) were treated with a psychosocial approach, including psychotherapy. After 6
months of treatment, clinical assessments were collected for 89 patients: 64 (71.9%)
showed no response, 9 (10.1%) response without remission and 16 (18.0%) were in
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remission; non-responder patients showed lower quality of life and higher disability scores
than responder patients.
Conclusions: In our sample of TRD patients, we documented substantial illness burden,
low perceived quality of life and poor outcome, suggesting an unmet treatment need in
TRD care in Italy.
Registration Number: ClinicalTrials.gov, number: NCT03373253.
Keywords: treatment resistant depression, treatment outcome, health-related quality of life, cohort study,
treatment pattern, real-world study, major depressive disorder
INTRODUCTION
Major depressive disorder (MDD) is a highly prevalent and
burdensome mental disorder (1). The lifetime risk of MDD
ranges 5–18% in the general population, with considerable
variations across countries (2, 3). A recent publication from
the World Health Organization (WHO) reported a prevalence
of about 5% for depression in the European region (4). MDD
is associated with social withdrawal, functional and vocational
impairment, medical morbidity and increased utilization of
health care services (1). According to WHO, MDD is the main
contributor to the global years lived with disability worldwide (4).
While the therapeutic goal of MDD is remission with
complete functional recovery (5), a sizeable subgroup of
patients reports residual or persistent symptoms of depression
despite receiving evidence-based antidepressant treatments (6).
Evidence indicates that the likelihood of remission decreases
with consecutive treatment lines (7). In the large, US, multi-
step Sequenced Treatment Alternatives to Relieve Depression
(STAR∗D) study there was a significant reduction of remission
chances after the second and the third treatment steps. Remission
rates were 36.8% for the first and 30.6% for the second treatments,
while in patients who had failed the first two treatments,
the remission rate dropped to 13.7% with the third and 13%
with the forth treatment steps (7). A similar pattern was
observed for response rates. In addition the greatest illness
burden (i.e., depression chronicity, psychiatric or general medical
comorbidity) was characteristic of those who required more
treatment steps.
According to the European regulatory authority, treatment
resistant depression (TRD) is defined as a major depressive
episode (MDE), in the context of MDD diagnosis, failing
to achieve adequate response after treatment with at least
two antidepressants given at adequate dose and duration
(8). With this definition, TRD affects 20–30% of MDD
patients (9). Other staging methods for TRD consider different
parameters, precluding consensus on the prevalence of the
condition (10–12).
Available evidence indicates that TRD patients experience
a dramatically higher burden of illness compared to patients
who respond to treatment, with more severe symptomatology,
poorer quality of life, higher disability, reduced life expectancy,
greater frequency of suicide attempts, and higher health care
costs (13–15).
Since there are no approved drugs in Europe for the
treatment of TRD, current pharmacological options in TRD
are as much the same as those available for the treatment of
MDD (1), and include selective serotonin reuptake inhibitors
[SSRI], serotonin-norepinephrine reuptake inhibitors [SNRI],
tricyclic antidepressants [TCA], monoamine oxidase inhibitors
[MAOI], and atypical antidepressants (16, 17). Esketamine,
in conjunction with a SSRI or SNRI, is the only drug
recently approved specifically for TRD in Europe (2019)
(18). Among non-pharmacological treatments, psychotherapy
and neurostimulation therapies, such as transcranial magnetic
stimulation (TMS) have been proposed, usually in combination
with oral medications. However, their efficacy in TRD is still
questionable (19). Electroconvulsive therapy (ECT) is highly
effective but is not widely available in Italy (20). Other non-
pharmacological approaches such as deep brain stimulation
(DBS) and vagal nerve stimulation (VNS) are invasive, with safety
and tolerability concerns (21).
In clinical practice, common treatment strategies to tackle
non-response in MDD involve switching to an alternative
antidepressant, adding an antidepressant (combination therapy)
or adding an augmentation agent (usually lithium, second-
generation antipsychotics [SGA] and thyroxine) to the ongoing
pharmacological therapy (22). Combining antidepressants or
augmenting with non-antidepressant medications are typically
employed when patients achieve partial response to the initial
medication regimen; however, combined therapy may be
associated with more severe side effects and poor tolerability. In
the case of non-response and/or poor tolerability of the initial
therapy, switching to another antidepressant is a common clinical
choice (23). An alternative approach is to combine common
drugs with psychotherapy or neurostimulatory treatments. In any
case, the optimal treatment sequence in TRD is yet to be defined.
Real-world evidence on patients with TRD is scarce (15, 24,
25), especially from European countries (26), and mainly derived
from retrospective studies based on administrative databases or
electronic health records (27–29). Within these studies, data on
prescribing patterns and illness outcome are sparsely reported
(24–26, 30). Real-world data are of paramount importance
since patients included in randomized clinical trials (RCTs) of
depression are poorly representative of the treatment-seeking
depressive patients in routinary clinical practice. Indeed, patients
included in RCT are relatively uncomplicated, without relevant
medical and psychiatric comorbidities, with absent suicidality,
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and higher likelihood of responsiveness, as reflected by the
high rate of placebo response (31). In addition, in the clinical
trial setting patients are more extensively assessed and more
frequently monitored than in clinical practice, and treatment
adherence is not a major issue (32). Real-world studies in the
MDD/TRD context are therefore needed to fill the gap between
clinical research and routinary clinical practice.
In light of this need, a cohort study was established in 2018
to collect real-world data from TRD patients treated in clinical
practice in several European countries (33, 34). Available data of
411 TRD patients with moderate-to-severe disease starting a new
antidepressant treatment and followed for a minimum 6 months
period were analyzed. Results from the overall European cohort
showed the substantial impact of TRD on patients and society
(33), and underlined the wide range of treatments used in clinical
practice and the poor response rates of these patients (34).
Given the lack of a widely shared and consolidated standard
of care and the possible difference among countries in the clinical
approach to TRD, it is important to describe the country specific
approach and prospective outcome in the management of TRD.
Therefore, the present investigation is aimed to describe
the socio-demographic and clinical characteristics, treatment
patterns and outcomes of the Italian patients included in the large
European TRD cohort, considering that about one third of the
patients of this cohort were recruited in Italy. The healthcare
resource use of these patients was also documented.
MATERIALS AND METHODS
Study Design and Participants
The present study is based on the Italian component of a
European, prospective, multicentric, observational cohort study
of TRD patients (ClinicalTrials.gov number, NCT03373253).
Study methods for the overall European cohort have been
previously described (33). The study was conducted in the
period February 2018 (first patient in) and January 2020 (last
visit of the last patient). Briefly, in- and outpatients aged
18 to 74 years, of both genders, with a diagnosis of MDD
(according to the Diagnostic and Statistical Manual of Mental
Disorders Fifth Edition [DSM-5] or the International Statistical
Classification of Diseases and Related Health Problems, 10th
Revision [ICD-10] criteria for MDD or Depressive disorder)
and fulfilling TRD criteria by the European Medicines Agency
(EMA) (i.e., treatment failure on at least 2 different oral
antidepressants, given at adequate dose and duration, as
evaluated by the Massachusetts General Hospital-Antidepressant
Treatment Response Questionnaire [MGH-ATRQ]) were
enrolled in the study. To be enrolled, patients had to have
moderate-to-severe depressive episode, as defined by a
Montgomery-Åsberg Depression Rating Scale (35) (MADRS)
≥20 and needed to be initiating a new treatment regimen
for MDD (i.e., any pharmacological or non-pharmacological
treatment, including neurostimulation and psychotherapeutic
interventions, prescribed to replace, or in addition to, the
previous treatment; switches to biosimilars or changes in dose
were not considered as new treatments) according to standard
care; treatment choice, dose and method of administration was
at the discretion of the prescribing physician.
Patients were excluded if they had: current or past psychotic
disorders, MDD with psychotic features, bipolar disorders or
intellectual disability according to DSM-5 or ICD-10; history of
suicidal behavior within 1 year prior to enrolment; homicidal or
suicidal ideation with intent within 1 month prior to entering
the study; history of moderate or severe substance disorder
(including alcohol) within 6 months prior to enrolment.
TRD patients were followed-up for a 12-month observation
period with a minimum of 6-months and an extended
observation period up to 6 months after enrollment of the last
patients (end of study). In the overall cohort, patients were
enrolled in multiple centers from Belgium (9 sites, 44 patients),
Germany (23 sites, 59 patients), Italy (22 sites, 124 patients),
the Netherlands (3 sites, 27 patients), Portugal (10 sites, 37
patients), Spain (16 sites, 71 patients) and the United Kingdom
(15 sites, 49 patients); in the present study, the Italian sub-cohort
was analyzed.
The study was conducted according to the Declaration of
Helsinki, with the approval of the study Local ethics review
boards. All patients provided written informed consent to
participate in the study; their capability to give consent was
judged by the treating physician.
Data Collection
Data were collected at baseline, at scheduled visits (every
6 months), and at study end. Data were also collected in
case of premature study withdrawal and clinically relevant
events, such as a change in treatment, admission to –
or discharge from – inpatient care, symptoms relapse or
MDE remission. Individual participant information was mainly
recorded from patient’s medical records; patients were also asked
to complete questionnaires for the self-assessment of quality of
life and functionality.
At baseline, patient’s socio-demographic characteristics,
history of the depressive disease, treatment history for the current
MDE, and comorbidities were recorded. Clinical evaluation was
performed at baseline and at each visit. Depression severity
was assessed through the MADRS (35) (range: 0–60, with
higher scores for higher depressive symptomology) and the
Clinical Global Impression of Severity (CGI-S) (36) (range:
1–7, with higher scores for more severe mental illness). Change
in depression severity was evaluated through the Clinical
Global Impression of Change (CGI-C) (36) (range: 1–7, with
lower scores for improvement and higher scores for worsening
of depression). Patient’s quality of life and functioning was
collected at baseline and scheduled visits. Quality of life was
assessed by the self-reported EuroQol 5-dimension 5-level
(EQ-5D-5L) instrument (37). The EQ-5D-5L questionnaire
assessed five dimensions (i.e., mobility, self-care, usual activities,
pain/discomfort and anxiety/depression), with five levels of
functioning (e.g., no problems, slight, moderate, severe and
extreme problems). Results on each dimension were converted
into a single utility index (generally ranging 0–1, with higher
scores for a better state of health) according to standard methods;
UK tariffs were used. The EQ-5D-5L questionnaire also included
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the EQ visual analog scale (EQ-VAS, range: 0–100, with higher
scores for better quality of life). Functional impact and disability
was evaluated by the self-reported Sheehan Disability Scale (SDS)
(38). In the SDS, patients are asked to rate the extent to which (1)
work, (2) social life or leasure activity, and (3) home life or family
resposibilities are impaired on a 10-point visual analog scale,
on which 0 is for normal function and 10 for severe funcional
impairment; the total SDS score is calculated by summig up the
3 rates items, and thus ranges from 0 to 30, with higher scores
for more severe impairment.
All pharmacological and non-pharmacological antidepressant
therapies initiated at baseline and during the study period as for
clinical practice were recorded.
Data on the healthcare resource utilization during the study
period, including hospitalization, inpatient and outpatient visits,
and intensive care unit (ICU) visits, were recorded.
Data Processing and Analyses
Analyses were based mainly on data collected at baseline
(available for all 124 patients) and at 6 months after baseline
(available for 98 patients).
Antidepressant pharmacological treatment classes were
categorized as: SSRI, SNRI, TCA, MAOI, and “other”
(e.g., trazodone, bupropion, mirtazapine, vortioxetine).
Non-antidepressant drugs were categorized as add-on or
augmentation medications (e.g., quetiapine, brexpiprazole,
aripiprazole, lithium). Combination therapy was defined as more
than one antidepressant medication in the absence of add-on
medication. Augmentation therapy was defined as antidepressant
medication(s) plus at least one add-on medication.
We derived treatment lines being received by patients from
baseline onward. Specifically, every treatment started at baseline
(between 7 days before and 14 days after baseline) was defined
as “first treatment line”. To be included in an appropriate
“treatment line,” a treatment had to last at least 30 days: patients
who started a treatment line at baseline but were lost to follow-up
within 1 month and/or had no post-baseline visit with MADRS
assessment were not taken into account in this analysis.
Remission and response status were defined according to the
MADRS score. In particular, remission was defined as a MADRS
score ≤10 and response (without remission) was defined as an
improvement ≥50% from baseline in the MADRS score, with a
MADRS >10.
The main study outcomes were the rates of patients with
remission and response status at 6 and 12 months after baseline
(only the assessments done during the visits which occurred,
respectively, between days 150 and 216 and between days 330 and
402 after baseline were taken into account). Change in patient’
condition according to the CGI-C score (vs. the baseline visit) at
6 month was also analyzed. Quality of life and functioning at 6
months were also described, overall and by clinical response.
Statistical Analysis
Continuous variables were presented as mean values (±standard
deviations) or median values (ranges), and categorical variables
were reported as numbers and percentages. The Kaplan-Meier
TABLE 1 | Baseline socio-demographic characteristics and clinical features,




Age (years), mean (sd) [range] 53.2 (9.8) [21–72]
Women, n (%) 82 (66.1)
Education level, n (%)
Primary school 15 (12.1)
Secondary school 50 (40.3)




Married/official partner 70 (56.5)
Not married/no official partner 31 (25.0)
Divorced 13 (10.5)







At home alone 21 (16.9)
At home with family, partner or friends 102 (82.3)
Psychiatric institution 1 (0.8)
Clinical features
MADRS score, mean (sd) [range] 31.1 (6.1) [20–47]
MADRS score categoriesa, n (%)
Moderate depression 88 (71.0)
Severe depression 36 (29.0)
CGI-S score, n (%)
Mildly ill 5 (4.0)
Moderately ill 59 (47.6)
Markedly ill 47 (37.9)
Severely ill 12 (9.7)
Among the most extremely ill patients 1 (0.8)
Psychiatric and medical history
Age (years) at MDD diagnosis, mean (sd) 37.3 (13.1)
Duration (years) of MDD, mean (sd) 16.0 (11.1)
First episode, n (%) 18 (14.5)
Previous depressive episodes, mean (sd)—median 5.2 (7.0) – 3.0
Duration (days) of current MDE, mean (sd) 97.5 (143.5)
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aModerate depression, MADRS score 20–34; Severe depression, MADRS score
>34. bTwenty-nine patients reported endocrine/metabolic disorders, 28 cardiovascular
diseases, 9 gastrointestinal diseases, 8 musculoskeletal diseases, 7 neurologic disorders,
and 5 genito-urinary diseases; other comorbidities were reported by <4% of patients.
CGI-S, Clinical Global Impression of Severity; MADRS, Montgomery-Åsberg Depression
Rating Scale; MDD, Major depressive disorder; MDE, major depressive episode; sd:
standard deviation.
method was used to estimate the survival curve for time to
treatment change.
RESULTS
In total, 124 Italian patients with TRD from 22 sites participated
in the TRD European cohort and were included in the
present analysis.
Baseline Demographic Characteristics,
Clinical Features and Medical History
At enrollment, the mean (SD) age was 53.2 (sd = 9.8) years
and 82 patients (66.1%) were women (Table 1). Most patients
had secondary (n = 50, 40.3%) or high school education (n =
44, 35.5%); 11 patients (8.9%) had University degrees. Seventy
patients (56.5%) were married or had an official partner; 42
(33.9%) were employed, 52 (42.0%) unemployed and 17 (13.7%)
were retired. The large majority of patients lived at home
with cohabitants (n = 102, 82.3%); one patient lived at a
psychiatric institution.
The mean age at onset of MDD was 37.3 (sd= 13.1) years and
the mean duration of the illness was 16.0 (sd = 11.1) years. The
mean number of previous depressive episodes was 5.2, ranging
from 0 to 43.
The current MDE had a mean duration of 97.5 (sd = 143.5)
weeks, ranging from 13 to 1,304 weeks, and was a recurrent
episode for over 85% of the patients; for treating it, 75 (60.5%),
35 (28.2%), and 14 (11.3%) patients had previously failed 2, 3 and
≥4 antidepressant drugs, respectively.
Fifty-five patients (44%) reported at least one ongoing
comorbidity at baseline (32 patients 2 or more comorbidities),
including both psychiatric and somatic ones; the most frequent
ongoing conditions were endocrine andmetabolic disorders (n=
29, 23.4%) and cardiovascular diseases (n = 28, 22.6%), followed
by gastrointestinal (n = 9, 7.3%), musculoskeletal (n = 8, 6.5%),
neurologic (n = 7, 5.6%), and genito-urinary diseases (n = 5,
4.0%). Other comorbidities were reported by <4% of patients.
The mean MADRS score at enrollment was 31.1 (sd = 6.1),
with 88 patients (71.0%) being classified as having moderate
depression (MADRS 20–34) and the remaining 36 (29.0%) as
having severe depression (MADRS>34). Based on the CGI-S
score (range: 1–7), 5 patients (4%) were categorized as mildly ill,
59 (47.6%) as moderately ill, 47 (37.9%) as markedly ill and 12
(9.7%) as severely ill; 1 patient had a CGI-S score of 7 (among the
most extremely ill patients).
Prior Failed Treatments and Successive
Treatment Lines
The most frequent failed antidepressant classes were SSRI (n =
96, 77.4%) and SNRI (n = 57, 46.0%), followed by TCA (n = 25,
20.2%); prior add-on drugs (SGAs) were reported by 17 patients
(13.7%) (Figure 1).
Information about drugs started at baseline was available
for 98 patients (Figure 1): 42 patients (42.9%) started a SSRI
(mainly sertraline, paroxetine, and escitalopram), 32 (32.7%) a
SNRI (venlafaxine and duloxetine), 15 (15.3%) a TCA (mainly
clomipramine), and 46 (46.9%) “other” antidepressant classes
(including 23 patients [23.5%] receiving vortioxetine, 14 [14.3%]
bupropion and 10 [10.2%] trazodone); 42 (42.9%) and 25 (25.5%)
patients started, respectively, add-on SGAs (mostly quetiapine
and aripiprazole) and add-on mood stabilizers (mostly lithium).
No patient was treated with MAOI drugs. Regarding non-
pharmacological approaches, no patient was treated with a
neurostimulation approach. According to baseline information,
14 Italian patients (11.3%) had been treated with a psychosocial
approach, including psychotherapy; in particualar, 7 patients
(5.6%) received cognitive behavioral therapy.
In terms of treatment strategies, 50 patients (51.0%) started
at baseline augmentation therapies, 18 (18.4%) combination
therapies, and 24 (24.5%) monotherapies; 6 patients (6.1%)
received a non-antidepressant drug (e.g., SGA) only.
According to Kaplan-Meier analysis, 73% of patients were
still on the treatment received at baseline after 6 months
(Supplementary Figure 1).
In the successive treatment line (n = 28), 19 patients
(68%) received augmentation therapy; combination therapy,
monotherapy and a non-antidepressant drug only were
prescribed to 3 patients each (data not shown).
Outcomes and Health Resource Utilization
At Month 6, 16 patients were reported as discontinued: 11
patients were lost to follow up; 2 died; 3 discontinued due to
“other” reasons. Data were excluded from the 6 months outcome
analysis for a further 18 patients who were still in the study
but whose visits did not meet the defined cut-off dates for a
Month 6 visit. We excluded one additional patient who had
missing MADRS information at month 6. In total, 35 patients
were not considered in the 6 month analysis (mean age: 52.2
years, % of women: 62.9%, mean MADRS: 29.9). All other 89
patients were included in this analysis, irrespective of treatment
strategy. Among them, 64 (71.9%) showed no response, 9 (10.1%)
response without remission and 16 (18.0%) remission (Figure 2).
The MADRS score decreased, on average, by 31.6% (sd = 31.4),
with a 6-month mean score of 21.5 (sd = 10.8): the mean score
was 26.3 (sd= 8.6) in 64 non-responder patients, 13.8 (sd= 3.7)
in 9 responder patients and 6.9 (SD 1.4) in 16 remitter patients.
At 6 months, 6 patients (6.7%) were classified as not at all ill,
10 (11.2%) as bordeline metally ill, 15 (16.9%) as mildly ill, 44
(49.4%) as moderately ill, 10 (11.2%) as markedly ill and 4 (4.5%)
as severely ill based on the CGI-S score. The corresponding
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FIGURE 1 | Prior failed antidepressive treatment and treatment started at baseline. *33 patients (26.6%) were treated with add-on mood stabilizers (16 patients
[12.9%] with lithium) at baseline (not documented whether treatment onging at baseline or started at baseline). AD, antidepressants; MAOI, monoamine oxidase
inhibitors; SGA, second-generation antipsychotics; SNRI, serotonin-norepinephrine reuptake inhibitors; SSRI, selective serotonin reuptake inhibitors; TCA,
Tricyclic antidepressants.
FIGURE 2 | Treatment response* among patients with treatment-resistant
depression at 6 months. *Remission: Montgomery-Åsberg Depression Rating
Scale (MADRS) score ≤10; response (without remission): ≥50% improvement
in the MADRS score, with MADRS>10.
numbers were 0, 1, 12, 38, 9 and 4 in non-responder patients,
2, 1, 2, 3, 1, and 0 in responder patients, and 4, 8, 1, 3, 0, and 0 in
remitter patients.
According to the CGI-C score, 30 patients improved much or
very much (33.7%), 29 patients minimally improved (32.6%) and
30 (33.7%) did not benefit from treatment (no change or worse) at
6 months (Table 2). The means of EQ-5D-5L and EQ VAS were
0.44 (sd = 0.25) and 43.9 (sd = 19.0) at baseline and 0.6 (sd =
0.2) and 57.5 (sd = 22.3) at 6 months. The mean of the SDS
scores decreased from 21.0 (sd = 5.7) at baseline to 15.0 (sd =
8.0) at 6 months. When patient-reported measures were analyzed
according to clinical response, we found mean EQ-5D-5L scores
of 0.6 in non-responder patients, 0.7 in responder patients and
0.9 in patients in remission; the corresponding mean values for
EQ-VAS were, respectively, 50.1, 64.6 and 81.9 (Table 2). As for
the disability, the mean SDS scores at 6 months was 18.6 in non-
responder patients, 12.6 in responder patients, and 5.0 in patients
with remission.
Outcomes data at the 12-months follow-up were available for
44 patients; 27 (61.4%) had no response, 7 (15.9%) achieved
response without remission and 10 (22.7%) achieved remission
(Supplementary Figure 2).
During the first 6 months of study, 11 patients (12.4%) were
hospitalized, with a median of 11 (range: 1–34) days spent in
hospital (Table 3). Sixty-three patients (70.8%) had at least one
outpatient consultation.
DISCUSSION
The present study provided original and interesting data on the
characteristics, the naturalistic treatment pattern and the clinical
outcome of a cohort of TRD patients with moderate to severe
depression treated in Italian clinical practice. We also reported
information on the health resource utilization of these patients.
A recent Italian study aimed at estimating the number
of patients with TRD and at characterizing the pattern of
drug use in the country (30). By applying TRD criteria by
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TABLE 2 | Change in depression severity at 6 months compared to the baseline visit (CGI-C score), and quality of life and disability at baseline and at 6 months in patients









remission N = 9
Remission
N = 16
CGI-C score*, n (%)
Very much improved 5 (5.6) 1 (1.6) 2 (22.2) 2 (17.6)
Much improved 25 (28.1) 9 (14.1) 3 (33.3) 13 (76.5)
Minimally improved 29 (32.6) 24 (37.5) 4 (44.4) 1 (5.9)
No change 18 (20.2) 18 (28.1) 0 (0) 0 (0)
Minimally worse 7 (7.9) 7 (10.9) 0 (0) 0 (0)
Much worse 5 (5.6) 5 (7.8) 0 (0) 0 (0)
EQ-5D-5L utility index, mean (sd) [N] 0.4 (0.3) [121] 0.6 (0.2) [85] 0.2 (0.2) [61] 0.7 (0.1) [8] 0.9 (0.1) [16]
EQ-VAS, mean (sd) [N] 43.9 (19.0) [123] 57.5 (22.3) [85] 50.1 (20.4) [61] 64.6 (15.0) [8] 81.9 (11.7) [16]
Total SDS, mean (sd) [N] 21.0 (5.7) [94] 15.0 (8.0) [61] 18.6 (5.9) [41] 12.6 (7.8) [7] 5.0 (4.0) [13]
CGI-C, Clinical Global Impression of Change; EQ-5D-5L, EuroQol 5-dimension 5-level; EQ-VAS, EuroQol visual analog scale; N, n. of patients with available data; sd, standard deviation;
SDS, Sheehan Disability Scale.
*compared with baseline visit.
TABLE 3 | Healthcare resource utilization between baseline and month 6 in
patients with treatment-resistant depression.
N = 89
Patients hospitalized, n (%) 11 (12.4)
N. of days in hospitala, median (range) 11 (1–34)
Patients visiting ICU, n (%) 4 (4.5)
Patients with day clinic visits, n (%) 6 (6.7)
Patients with night clinic visits, n (%) 1 (1.1)
Patients with outpatient consultation, n (%) 63 (70.8)
ICU, intensive care unit.
aAmong hospitalized patients.
the EMA, the authors estimated over 101,000 Italian adults
affected by TRD. They also reported frequent use of combination
and augmentation therapy to treat the disease. That study
was, however, a retrospective record-linkage study based on
administrative databases and did not provided clinical outcome
data (30). Collecting prospectively and ad hoc patient-level
information on disease course, the current study represents,
therefore, an important complementary source of data on TRD
in Italy.
Our study showed the negative impact TRD has on patients
in terms of employment status, quality of life and functioning,
and documented the frequent use of SSRI and SNRI and of
augmentation strategies in the everyday Italian clinical practice.
The moderate to severe MDE lasted on average almost 2
years, without any treatment response in more than 70% of the
cases, suggesting a substantial disease burden over time. The
poor response and remission rates observed at 6 and 12 months
seem to reflect the difficult-to-treat nature of TRD: 71.9% of
the patients were still non-responder to the treatment at month
6, with a mean MADRS score of 26.3, indicanting persistence
of clinically relevant depressive symptoms. These results were
similar to those observed in overall European cohort (34).
Given such negative outcomes, it is surprising that no
patient in the Italian cohort was treated with neurostimulatory
techniques and that the use of psychotherapy was very limited.
In particular, psychosocial therapy was prescribed to 7% of our
Italian patients but to 19.2% of patients in the overall Euoropean
cohort (34). In a recent Danish study, psychotherapy was used in
18% of TRD patients (39). Our findings are aligned with the poor
availability and spread of such techniques in Italianmental health
departements; it is in any case worth to mention that information
on the use of private psychotherapists is not available in the study.
In line with the overall European sample (33), at baseline, our
patients had already suffered fromMDD for over a decade. About
2 out of 3 of our patients were female, in line with the well-
known sex ratio in the prevalence of depression (1). The mean
duration of the MDE ongoing at baseline was almost 2 years
and a considerable proportion of patients had experienced 3 or
more previous drug failures during the ongoing MDE. A high
proportion of patients, almost 50%, reported at least one ongoing
comorbidity at baseline, either psychiatric or physical. The most
frequent conditions were endocrine, metabolic disorders and
cardiovascular diseases.
Long duration of current MDE together with the failure of
several antidepressant treatments are main contributors to the
high burden of disease of TRD condition, that is also associated
with higher rates of psychiatric and physical comorbility, shorter
life expectancy and higher mortality than non-TRD episodes
(27, 28, 40, 41).
Confirming the high burden of TRD, our patients showed low
quality of life and poor functioning, together with a substantial
degree of disability. In particular, we observed a mean utility
value derived from EQ-5D-5L of 0.44, similar to that reported
in a recently published French TRD cohort (26). The much
lower employment rate in our study (34%, which increased to
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39% when calculated excluding retired patients) compared to
that reported for the Italian population (63% among individuals
aged 20–64 years in 2018 according to the Italian National
Institute of Statistics) is not unexpected and confirms the
personal and social burden of TRD. The negative impact of
MDD in general, and TRD in particular, on work functioning,
including employment status, has been widely reported in the
literature (15, 42).
Describing the treatment approaches, we documented a
widespread use of augmentation therapy, mostly with SGA,
which increases as treatment changes. At enrolment, previously
failed augmentation therapy was reported by ∼14% of patients,
while it was received by a considerable higher proportion
of patient at baseline (51%) and at the successive treatment
step (68%). An increase in the use of augmentation with
successive treatment lines was reported also in the overall
European cohort, but with lower prevalences (i.e., 36.7% at
baseline and 47.2% at the successive treatment step) (34).
Although a specific pharmacological treatment has not been
established for TRD, augmentation is a mainstay in the
pharmacotherapy of TRD and more severe/difficult to treat
MDD (16), with multiple clinical trials and meta-analyses
focused on the efficacy of SGA and lithium in MDD patients
failing on an antidepressant (22, 23). Widespread use of a
polypharmaceutical approach and augmentation in MDD was
observed in a large, European, cross-sectional study, which
also reported an association between augmentation/combination
therapy and resistance to prior antidepressant therapy (43). In
the only available Italian study on TRD 57% of patients were
prescribed an add-on treatment starting from the third line of
therapy (30).
An increasing prescription of SGA in MDD has been
documented in the last years across various countries (44, 45),
including European ones (46). Noteworthy, the SGA quetiapine
got approval by the EMA as add-on medication to ongoing
antidepressants in patients with MDDwho have had sub-optimal
response to treatment with other antidepressants [Quetiapine XR
EPAR] (47). A recent meta-analysis showed a relatively limited
efficacy of add-on treatment with SGA compared with placebo
in TRD, with a pooled mean difference in the mean change from
baseline in the MADRS score of 2.5 for SGA vs. placebo (48).
In our study, lithium augmentation was less frequently
prescribed than SGA, as reported by others (43). Most
of the available evidence is on the efficacy of lithium
augmentation with TCAs, which are not widely used in
contemporary clinical practice (49) (as also observed in the
present study). On the contrary, the efficacy of lithium
augmentation with SSRI and SNRI antidepressants is not well-
documented (50). This observation, together with the diffuse
negative perception of lithium side effects and safety concerns
(51) and the need for monitoring of the serum lithium
concentration and endocrine and renal function (50), may
explain the lower use of lithium over SGA augmentation in
clinical practice.
In terms of antidepressants, SSRI and SNRI represented
the most frequently previously failed classes of antidepressants
for the treatment of the index MDE as well as the treatments
chosen most commonly at baseline in monotherapy or
in combination; this indicates a still widespread use
in clinical practice of these 2 antidepressant classes
that are representative of the current Italian standard
of care.
In general, we observed some improvements in depression
severity, quality of life, functioning and disability at 6 months,
with 32.6% of patients being classified as minimally improved,
28.1% as much improved and 5.6% as very much improved
by the CGI-C score, and with scores of EQ-5D-5L and EQ-
VAS increasing (respectively from 0.4 to 0.6 and from 43.9
to 57.5, on average) and scores of SDS decreasing (from
21.0 to 15.0, on average). However, response rates at 6
months were generally poor (remission: 19%, response: 10%);
data at 12 months, limited to 44 patients with available
information, did not demonstrate any meaningful improvement
in outcomes with 6 additional months of treatment (remission:
15.9%, response: 22.7%). Notewhorty, disability evaluations
with SDS and quality of life with EQ-5D-5L and EQ-VAS
scores were consistent with MADRS outcomes, showing a
substantial burden of disease in non-responder patients and
suggesting a consistency between the physician’s assessment of
the disease and the patient’s perception of their health and quality
of life.
Although measures of function and quality of life are
important secondary outcomes, remission, i.e., complete relief
of depressive symptoms, is the most clinically relevant goal in
MDD. Patients achieving remission have better functioning
and prognosis and are much less likely to relapse than
those achieving response with residual symptomatology (5).
Low response and remission rates in TRD with standard
care were reported by others (24, 25, 52). In particular,
in a US, prospective, observational study of 124 TRD
patients receiving treatment as usual, the 6-, 12- and 24-
months remission (i.e., 30-item Inventory of Depressive
Symptomatology-Self Report [IDS-SR-30] ≤14) rates were
2.5, 3.6, and 7.8%, respectively; the corresponding response
(i.e, ≥50% IDS-SR-30 improvement) rates were, respectively,
8.4, 11.6, and 18.4% (24). Our results, consistently with
those from other studies, underscore the unmet need
for better treatment modalities for TRD, as the current
options have a low chance to provide clinically desirable and
long-term effects.
Because of the timeline of esketamine nasal spray approval
(November 2019 by the EMA and March 2020 by the Italian
Medicines Agency) and of its commercial availability in Italy
(October 2020), our study did not capture data of this new
treatment option for TRDpatients, for which only data fromRCT
are available; it will be relevant to document its use and associated
outcomes in more naturalistic settings.
This is the first real-world prospective study on TRD
conducted in Italy; however, the sample size is relatively small
compared to other studies. Among the other limitations, the
diagnosis of MDD was made exclusively by clinical assessment
according to standard criteria and no (semi)structured interview
was administered. In addition, data collected in our study did
not allow to associate outcomes to specific treatment strategies.
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Furthermore, outcomes data at 6 and 12 months of follow-up
were available only for a proportion of patients; this was due
to a number of reasons, including lost to follow up, patients
drop out, study end (i.e., the study ended 6 months after the
recruitment of the last patient), lack of MADRS and other
clinical/patient reported outcome data, and the fact some patients
did not have visits meeting criteria for a month 6 (i.e., occurred
between day 150 and day 216 after baseline) or a month 12
visit (between day 330 and day 402). In particular, outcome
data at 12 months were available for <40% of the originally
recruited patients, and thus such results need to be interpreted
with caution.
Our study has, however, major strengths, including the
prospective design, the inclusion of patients encountered in
routine clinical practice, the involvement of a number of sites
across the various Italian Regions, and the ad-hoc prospective
collection of clinical and patients reported outcomes through the
observation period.
CONCLUSIONS
Results from the present study clearly showed the negative
impact of TRD in terms of chronicity of the symptomatology,
impairment in quality of life and functioning, and documented
the substantial burden experienced by real-world TRD
patients in Italy as in other European Countries. We also
documented the widespread use of SSRI and SNRI and
of augmentation strategies and the unfrequent use of a
psychosocial approach, including psychotherapy, in the everyday
Italian clinical practice. The study shows that, despite the
multiple treatment options, the disease remains a complex and
challenging condition and suggests an unmet treatment need in
TRD care.
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